Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik sold 12,795 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $38.07, for a total value of $487,105.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) belongs to Healthcare sector. and weekly performance is 12.11%. On last trading day company shares ended up $40.36. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) distance from 50-day simple moving average (SMA50) is 7.64%.
Companhia Siderurgica Nacional (NYSE:SID) has received a “BB” credit rating from analysts at Morningstar. The firm’s “BB” rating indicates that the company is an above-average default risk. They also issued a neutral credit outlook for the company and gave their stock a three star rating. Companhia Siderurgica Nacional (NYSE:SID) shares fell -3.68% in last trading session and ended the day at $4.19. Companhia Siderurgica Nacional (NYSE:SID) quarterly performance is -1.41%.
NCI Building Systems (NYSE:NCS) released its earnings data on Monday. The company reported $0.10 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.09 by $0.01, Stock Ratings News reports. The company had revenue of $361.63 million for the quarter, compared to the consensus estimate of $352.68 million. During the same quarter last year, the company posted $0.02 earnings per share. NCI Building Systems’s revenue was up 14.0% compared to the same quarter last year. On 08 September, NCI Building Systems Inc. (NYSE:NCS) shares fell -0.54% and was closed at $20.09. NCS EPS growth in last 5 year was -15.00%. NCI Building Systems Inc. (NYSE:NCS) year to date (YTD) performance is 14.54%.
On 28 Aug 2014 Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), a specialty biopharmaceutical company, today announced that data from trials evaluating the use of collagenase clostridium histolyticum (CCH) for treating two Dupuytren’s contracture (DC) cords concurrently in adult patients with a palpable cord will be presented at the upcoming 69th Annual Meeting of the American Society for Surgery of the Hand (ASSH) being held in Boston on September 18-20, 2014. XIAFLEX® (CCH) is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord. Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) ended the last trading day at $20.46. Company weekly volatility is calculated as 4.34%and price to cash ratio as 22.99. Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) showed a weekly performance of 10.00%.
On 5 Aug 2014 Westbury Bancorp, Inc. (NASDAQ:WBB), the holding company (the “Company”) for Westbury Bank (the “Bank”), today announced net income of $69,000 for the third quarter ended June 30, 2014, compared to a net loss of $1.8 million for the quarter ended March 31, 2014, and a net loss of $446,000 for the third quarter ended June 30, 2013. Net loss for the nine months ended June 30, 2014 was $1.7 million compared to net income of $721,000 for the nine months ended June 30, 2013.Westbury Bancorp, Inc. (NASDAQ:WBB) shares fell -0.99% in last trading session and ended the day on $15.04. its return on assets is -0.30%. Westbury Bancorp, Inc. (NASDAQ:WBB) quarterly performance is 3.51%.